{"disease":{"id":"bacterial-skin-infections","name":"bacterial skin infections"},"drugs":{"marketed":[{"drug_id":"omadacycline-tosylate","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nuzyra","generic_name":"OMADACYCLINE TOSYLATE","company_name":"Paratek Pharms","drug_phase":"marketed","molecular_target":"","drug_class":"Tetracycline-class Antibacterial [EPC]","quality_score":56,"revenue":null,"mechanism":"Nuzyra works by inhibiting protein synthesis in bacteria, ultimately leading to their death."},{"drug_id":"delafloxacin","indication_name":"Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Baxdela","generic_name":"DELAFLOXACIN","company_name":"Melinta","drug_phase":"marketed","molecular_target":"","drug_class":"Fluoroquinolone Antibacterial","quality_score":65,"revenue":null,"mechanism":"Baxdela works by blocking bacterial enzymes that replicate DNA."},{"drug_id":"bacitracin","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"BACITRACIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Tyrosine-protein kinase Lck","drug_class":"bacitracin","quality_score":27,"revenue":null,"mechanism":""},{"drug_id":"cortisone-acetate","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortone","generic_name":"CORTISONE ACETATE","company_name":"","drug_phase":"marketed","molecular_target":"Corticosteroid-binding globulin","drug_class":"alpha-Adrenergic Agonist [EPC]","quality_score":29,"revenue":null,"mechanism":""},{"drug_id":"sulfadiazine","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Sulfadiazine","generic_name":"SULFADIAZINE","company_name":"Eli Lilly","drug_phase":"marketed","molecular_target":"5-hydroxytryptamine receptor 2A","drug_class":"Sulfonamide Antibacterial [EPC]","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"ceftaroline","indication_name":"Acute bacterial skin and skin structure infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ceftaroline Fosamil","generic_name":"CEFTAROLINE","company_name":"Abbvie","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":47,"revenue":null,"mechanism":"Ceftaroline works by inhibiting bacterial cell wall synthesis through binding to penicillin-binding proteins."},{"drug_id":"chlortetracycline","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aureomycin","generic_name":"CHLORTETRACYCLINE","company_name":"","drug_phase":"marketed","molecular_target":"Protein-arginine deiminase type-4","drug_class":"chlortetracycline","quality_score":33,"revenue":null,"mechanism":""},{"drug_id":"neomycin","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"NEOMYCIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 1","drug_class":"Aminoglycoside Antibacterial","quality_score":53,"revenue":null,"mechanism":""},{"drug_id":"hydrocortisone","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortef","generic_name":"hydrocortisone","company_name":"Generic (originally Merck/Upjohn)","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"Corticosteroid [EPC]","quality_score":42,"revenue":null,"mechanism":""},{"drug_id":"polymyxin-b","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cortisporin","generic_name":"POLYMYXIN B","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Polymyxin-class Antibacterial","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"silvadene","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Silvadene","generic_name":"Silver Sulfadiazine","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"bacterial cell membrane and cell wall","drug_class":"sulfonamide antimicrobial","quality_score":65,"revenue":null,"mechanism":"Silver sulfadiazine acts on bacterial cell membrane and cell wall to produce bactericidal effect."},{"drug_id":"cortisol","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Cortisol","company_name":"University of Zurich","drug_phase":"marketed","molecular_target":"Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"pramocaine","indication_name":"Minor Bacterial Skin Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"pramocaine","company_name":"","drug_phase":"unknown","molecular_target":"Sigma non-opioid intracellular receptor 1, Sodium channel alpha subunits; brain (Types I, II, III), Membrane-associated progesterone receptor component 1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":13,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT03137173","title":"Ceftobiprole in the Treatment of Patients With Acute Bacterial Skin and Skin Structure Infections","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":679,"lead_sponsor_name":"Basilea Pharmaceutica","has_results":true},{"nct_id":"NCT03405064","title":"Comparative Study of Levonadifloxacin (IV and Oral) With Linezolid (IV and Oral) in Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":501,"lead_sponsor_name":"Wockhardt","has_results":false},{"nct_id":"NCT02961764","title":"Evaluation of a New Critical Pathway for Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Allergan","has_results":true},{"nct_id":"NCT03176134","title":"A Study of Safety and Efficacy of MK-1986 (Tedizolid Phosphate) and Comparator in Participants From Birth to Less Than 12 Years of Age With Acute Bacterial Skin and Skin Structure Infections (MK-1986-018)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":100,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true}],"total":4},"guidelines":[],"source":"Drug Landscape verified database"}